BIRC5 and acute lymphoblastic leukemia: In a proof of concept study, using a xenograft mouse model of primary ALL, the knockdown of survivin by shRNA in combination with chemotherapy resulted in no detectable minimal residual disease, demonstrating that targeting survivin can overcome chemotherapy resistance [144].